Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-018-4978-5
Abstract: PurposeIdentification of effective and reliable biomarkers that could be used to predict the efficacy of endocrine therapy is of crucial importance to the management of oestrogen receptor positive (ER+) breast cancer (BC). KIF18A, a key… read more here.
Keywords: endocrine therapy; kif18a; benefit endocrine; biomarker ... See more keywords